US 9,388,221 · Application 13/772,893 · Granted Jul 12, 2016
US 9,388,221
Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies
Estimated expiration
February 1, 2026
Expired 249 days ago
Earliest effective filing
Feb 1, 2006
+ 20 years
Feb 1, 2026
PTA +0d
Feb 1, 2026
TD applied
Feb 1, 2026
Final
Feb 1, 2026
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- February 21, 2013
- Earliest effective filing
- February 1, 2006
- Issue date
- July 12, 2016
- PTA
- 0 days
- Base expiry (before PTA)
- February 1, 2026
February 1, 2006 + 20 years = February 1, 2026
- Continuation of application 11/883,495, filed May 13, 2008, issued as US 8,404,244
- National stage entry of application PCTUS2006003601, filed Feb 1, 2006
- National stage entry of application PCTUS2006003601, filed Feb 1, 2006
- PRO60/649,249 — Provisional — not used for base term
- PRO60/697,655 — Provisional — not used for base term
- PRO60/752,268 — Provisional — not used for base term
- PRO60/649,249 — Provisional — not used for base term
- PRO60/697,655 — Provisional — not used for base term
- PRO60/752,268 — Provisional — not used for base term
- PRO60/649,249 — Provisional — not used for base term
- PRO60/697,655 — Provisional — not used for base term
- PRO60/752,268 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to February 1, 2026
US 8,404,244· Application 11/883,495Capping patent
Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies
- Filing date
- May 13, 2008
- Earliest effective filing
- Feb 1, 2006
- Issue date
- Mar 26, 2013
- PTA
- +1191 days
- Calculated expiration
- May 7, 2029
National stage entry of PCTUS2006003601, filed Feb 1, 2006
Feb 1, 2006 + 20y + 1191d PTA = May 7, 2029
US 9,388,221· Application 13/772,893(from application 13/772,893)Capping patent
Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies
- Filing date
- Feb 21, 2013
- Earliest effective filing
- Feb 1, 2006
- Issue date
- Jul 12, 2016
- PTA
- 0 days
- Calculated expiration
- Feb 1, 2026
Continuation of 11/883,495, filed May 13, 2008, issued as US 8,404,244
National stage entry of PCTUS2006003601, filed Feb 1, 2006
National stage entry of PCTUS2006003601, filed Feb 1, 2006
Feb 1, 2006 + 20y = Feb 1, 2026
US 10,981,127· Application 15/564,092(from application 15/564,092)
Mixing group and method for mixing two compounds
- Filing date
- Oct 3, 2017
- Earliest effective filing
- Apr 15, 2016
- Issue date
- Apr 20, 2021
- PTA
- +462 days
- Calculated expiration
- Jul 21, 2037
National stage entry of PCTIB2016052151, filed Apr 15, 2016
Apr 15, 2016 + 20y + 462d PTA = Jul 21, 2037
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 13/772,893 · US 9,388,221
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 9,388,221: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US9388221Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.